Amici Capital’s Sarepta Therapeutics SRPT Stock Holding History

Amici Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-25,000	Closed	-$477K	–	120
2016 Q2	$477K	Hold	25,000	–	–	0.09%	99
2016 Q1	$488K	Buy	+25,000	New	+$437K	0.06%	91
2015 Q3	–	Sell	-19,150	Closed	-$583K	–	158
2015 Q2	$583K	Hold	19,150	–	–	0.02%	120
2015 Q1	$254K	Buy	+19,150	New	+$255K	0.01%	117
2014 Q4	–	Sell	-21,978	Closed	-$464K	–	136
2014 Q3	$464K	Buy	+21,978	New	+$496K	0.02%	136

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Amici Capital's SRPT Position: Q3 2016 in Review

Amici Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 25,000 shares — an estimated $477K sold.

Amici Capital first reported a position in SRPT in Q3 2014 and held it in 5 quarters. The position peaked at $583K in Q2 2015. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

Amici Capital reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
Amici Capital sold 25,000 Sarepta Therapeutics shares in Q3 2016, an estimated $477K.
Amici Capital first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 5 quarters.
Amici Capital's Sarepta Therapeutics position peaked at $583K in Q2 2015.
186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Amici Capital's 13F filing for Q3 2016, filed 14 Nov 2016.